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OBJECTIVES The aim of the present study was to determine whether troglitazone reduces neointimal tissue
proliferation after coronary stent implantation in patients with non–insulin dependent
diabetes mellitus (NIDDM).
BACKGROUND Increased in-stent restenosis in patients with diabetes mellitus is due to accelerated neointimal
tissue proliferation after coronary stent implantation. Troglitazone inhibits intimal hyperpla-
sia in experimental animal models.
METHODS We studied 62 stented lesions in 52 patients with plasma glucose levels (PG) $11.1
mmol/liter at 2 h after 75 g oral glucose load. The study patients were randomized into two
groups: the troglitazone group of 25 patients with 29 stents, who were treated with 400 mg
of troglitazone, and the control group of 27 patients with 33 stents. All patients underwent
oral glucose tolerance tests before and after their six-month treatment period. The sum of PG
(SPG) and the sum of insulin levels (SIRI) were measured. Serial (postintervention and at
six-month follow-up) intravascular ultrasound studies were performed. Cross-sectional
images within stents were taken at every 1 mm, using an automatic pullback. Stent areas (SA),
lumen areas (LA), and intimal areas (IA 5 SA 2 LA) were measured and averaged over a
number of selected image slices. The intimal index was calculated as intimal index 5 averaged
IA/averaged SA 3 100%.
RESULTS There were no differences between the two groups before treatment in SPG (31.35 6 3.07
mmol/liter vs. 32.89 6 4.87 mmol/liter, respectively, p 5 0.2998) and SIRI (219.6 6 106.2
mU/liter vs. 209.2 6 91.6 mU/liter, respectively, p 5 0.8934). However, reductions in SPG
at the six-month follow-up in the troglitazone group were significantly greater than those in
the control group (221.4 6 8.8% vs. 24.5 6 7.4%, respectively, p , 0.0001). Likewise,
decreases in SIRI were greater in the troglitazone-treated group (231.4 6 17.9% vs. 21.9 6
15.1%, respectively, p , 0.0001). Although, there were no differences between the two groups
in SA at postintervention (7.4 6 2.2 mm2 vs. 7.3 6 1.7 mm2, respectively, p 5 0.9482) and
at follow-up (7.3 6 2.3 mm2 vs. 7.3 6 1.8 mm2, respectively, p 5 0.2307), the LA at
follow-up in the troglitazone group was significantly greater than that in the control group
(5.3 6 1.7 mm2 vs. 3.7 6 1.7 mm2, respectively, p 5 0.0002). The IA at follow-up in the
troglitazone group was significantly smaller than that in the control group (2.0 6 0.9 mm2
vs. 3.5 6 1.8 mm2, respectively, p , 0.0001). This was also true for intimal index (27.1 6
11.5% vs. 49.0 6 14.4%, respectively, p , 0.0001).
CONCLUSIONS Serial intravascular ultrasound assessment shows that administration of troglitazone reduces
neointimal tissue proliferation after coronary stent implantation in patients with NIDDM.
(J Am Coll Cardiol 2000;36:1529–35) © 2000 by the American College of Cardiology
Although coronary stent implantation has been shown to
reduce restenosis rates compared with balloon angioplasty,
in-stent restenosis remains a significant clinical problem,
especially in patients with diabetes mellitus (DM) (1–4). A
recent study using serial intravascular ultrasound (IVUS)
showed that increased restenosis in DM is due to exagger-
ated neointimal tissue proliferation after coronary stent
implantation (5). It has been reported that troglitazone, a
novel insulin-sensitizing agent, inhibits vascular smooth
muscle cell growth in experimental models (6–9). However,
the effect of troglitazone on neointimal tissue proliferation
after coronary stent implantation was unclear. Therefore, we
attempted to determine by means of serial IVUS studies
whether troglitazone reduces neointimal tissue proliferation
after coronary stent implantation in patients with non–
insulin dependent diabetes mellitus (NIDDM).
METHODS
Study patients. From September 1997 through February
1999, a total of 187 patients with 244 lesions underwent
coronary stent implantation using Palmaz-Schatz coronary
stents (Johnson & Johnson) and MultiLink stents (Ad-
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vanced Cardiovascular System, Temecula, California) in
Kobe General Hospital. Sixty-eight lesions from 55 patients
with NIDDM were studied. Inclusion into the study was
based on the World Health Organization criteria (10): a
plasma glucose level (PG) $11.1 mmol/liter (200 mg/dl) at
2 h after 75 g oral glucose load. Exclusions in this study
included: 1) patients with previously treated DM (oral
hypoglycemic agents or insulin); 2) patients with fasting PG
$7.77 mmol/liter (140 mg/dL); 3) patients with liver or
renal dysfunction; 4) ostial lesions or bifurcational lesions; 5)
lesions with reference vessel diameter ,2.5 mm; 6) lesions
treated with more than two stents; and 7) lesions with
average stent area ,5 mm2 as measured by postinterven-
tional IVUS.
Beginning two days before scheduled angioplasty, pa-
tients were randomly assigned to two treatment groups: the
troglitazone group of 28 patients with 35 stents, treated
with 400 mg of troglitazone and dietary stabilization, and
the control group of 27 patients with 33 stents, treated with
dietary stabilization only. All patients were seen and exam-
ined monthly to monitor their general well-being and to
identify potential adverse reactions, including liver dysfunc-
tion. At each visit, body weight, blood pressure, fasting PG,
and serum chemical and hematological profiles, including
liver enzyme levels, were determined. Our institutional
ethics committee approved the protocol, and patients gave
written, informed consent before randomization.
Baseline and final investigation. All patients underwent a
75-g oral glucose tolerance test (OGTT) 4 6 1 days before
coronary stent implantation and 2 6 1 days before
follow-up angiography. After fasting overnight, blood sam-
ples were obtained from each patient at baseline and at 1 h
and 2 h after the glucose load. The PGs were measured by
the enzymatic method using a Glucose Analyzer 1140
(Kyoto Daiichi Kagaku, Kyoto, Japan), and immunoreactive
insulin levels (IRIs) were measured by radioimmunoassay
with the use of insulin Riabead II (Dainabot, Tokyo, Japan).
The sum of plasma glucose (SPG 5 fasting PG 1 1 h
PG 1 2 h PG) and the sum of insulin levels (SIRI 5 fasting
IRI 1 1 h IRI 1 2 h IRI) were calculated.
Blood chemistry analyses, including glycosylated hemo-
globin A1c levels and lipid levels, were performed at the
same time. Glycosylated hemoglobin A1c was measured
with the use of Hi-Auto A1c HA-8121 (Kyoto Daiichi
Kagaku). Total cholesterol and triglyceride levels were
measured by the enzymatic method. High-density lipopro-
tein (HDL) cholesterol levels were measured in plasma after
precipitation of low-density lipoprotein (LDL) and very-
low-density lipoprotein. The LDL cholesterol concentra-
tions were calculated using the following formula: LDL
cholesterol 5 total cholesterol 2 HDL cholesterol 2
(triglyceride/5) (11).
Stent implantation. Palmaz-Schatz stents and MultiLink
stents were implanted according to standard protocols. The
IVUS was used to guide high-pressure adjunctive balloon
inflation to achieve targeted stent expansion. The targeted
expansion was a minimal stent area of $80% of the average
of the proximal and distal reference lumen cross-sectional
areas, by IVUS as well as complete stent-vessel wall appo-
sition. All patients received 160 mg of aspirin and 200 mg
of ticlopidine. The duration of ticlopidine treatment was
four weeks.
Quantitative angiographic analysis. Quantitative coro-
nary angiography was performed, using an automated edge
detection system CMS (Medis Medical Imaging Systems),
by a single individual who was unaware of the patients’
treatment assignments. A contrast-filled nontapered cathe-
ter tip was used for calibration. Minimal lumen diameter
(MLD), reference diameter, percent diameter stenosis, and
the diameter of the maximally inflated balloon were mea-
sured. Measurements from multiple projections were per-
formed, and results from the “worst” views were recorded. A
balloon-vessel ratio was calculated as the diameter of an
inflated balloon divided by the coronary reference diameter.
Intravascular ultrasound imaging. The IVUS imagings
were performed after intervention (following the final bal-
loon inflation) and at follow-up (six months’ post-stent
implantation). After administration of 1 to 2 mg of intra-
coronary isosorbide dinitrate, the 30-MHz, 3.2F IVUS
catheter (Cardiovascular Imaging System) was advanced to
the distal site in the coronary artery beyond the target lesion.
Continuous images of the coronary artery, from beyond the
target lesion to the aorto-ostial junction, were obtained as
the ultrasound catheter was slowly withdrawn at 0.5 mm/s
using a motorized pullback device. The IVUS images were
recorded on a 0.5-inch VHS videotape for off-line analysis.
The IVUS examinations were considered suitable for anal-
ysis if images were free from apparent ultrasound artifacts,
such as oblique catheter positioning or nonuniform rota-
tional distortion.
Quantitative IVUS measurements. With the use of
computer-assisted planimetry (Tape-Measure, Indec Sys-
tem), quantitative IVUS measurements were performed by a
single individual who was blinded to the patients’ treatment
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assignments. The IVUS recordings after stent implantation
and at follow-up were replayed on a video screen, and
cross-sectional images within stents were selected at every
1 mm (with a pullback speed of 0.5 mm/s, each 2 s of video
playback corresponds to 1 mm of axial length). Individual
image slices were digitized and cross-sectional stent areas
(SA), cross-sectional lumen areas (LA), and intimal areas
(IA 5 SA 2 LA) were measured and averaged over a
number of selected slices. When the tissue encompassed the
catheter, the lumen was assumed to be the physical size of
the imaging catheter. Therefore, 1.0 mm was the smallest
MLD, and 0.8 mm2 was the smallest cross-sectional LA
that could be measured before intervention (12). Because it
was difficult to measure SA accurately in image slices at
central articulation, the image slice at central articulation
was excluded from the analysis. An intimal index was
calculated as intimal index 5 averaged IA/averaged SA 3
100%. Reproducibility of the IVUS measurements have
been previously reported (13).
Statistical analysis. Quantitative data are presented as
mean 6 SD. Treatment groups were compared by analysis
of covariance of change from baseline value, with baseline as
a covariate. Differences in categorical variables were ana-
lyzed by the Fisher exact probability test, and differences in
continuous variables were compared between the two
groups using the Mann-Whitney U test. Clinical, angio-
graphic, and procedural characteristics and IVUS measure-
ments were determined using a lesion-based assessment.
Previous studies have shown that stented lesions behave
independently with regard to restenosis when multiple
lesions are treated in the same patient (14). A two-side value
of p , 0.05 was considered statistically significant. Patients
who discontinued the assigned treatment were excluded
from the final analysis. Thus, study groups were compared
by per-protocol analysis.
RESULTS
Troglitazone was well tolerated in 25 of the 28 patients in
the troglitazone group. Two patients who experienced
dizziness and one patient who had skin eruption after the
beginning of troglitazone treatment were withdrawn from
the study. No patient had persistent abnormalities in labo-
ratory variables, including liver enzyme levels. Finally, 62
stented lesions in 52 patients underwent follow-up IVUS
study. All patients underwent follow-up angiography as a
part of the study protocol. At the time of follow-up, three
patients had recurrent symptoms; however, none of the
patients presented with unstable angina or myocardial
infarction.
Selected demographic and clinical characteristics of the
52 patients are shown in Table 1. There were no statistically
significant baseline differences between the two groups.
Angiographic and procedural characteristics are also shown
in Table 1. There were no significant differences in target
vessels, angiographic reference diameter, MLD, lesion
length, stent types, balloon-artery ratio, or final balloon
pressure between the two groups.
Table 1. Clinical, Angiographic and Procedural Characteristics at Baseline
Variable
Troglitazone Group
(n 5 29 stents)
Control Group
(n 5 33 stents) p Value
Age (yr) 61 6 11 60 6 10 0.9887
Gender: male/female 23/6 27/6 .0.9999
Body mass index (kg/m2) 24.6 6 2.5 25.1 6 3.5 0.7941
Systolic blood pressure (mm Hg) 134 6 21 126 6 22 0.1604
Diastolic blood pressure (mm Hg) 67 6 10 69 6 12 0.6066
Risk factors: no. (%)
Hypertension 13 (45) 13 (39) 0.7974
Hyperlipidemia 20 (69) 23 (70) .0.9999
Current smoking 5 (17) 6 (18) .0.9999
Treatments: no. (%)
HMG-CoA reductase inhibitors 20 (69) 21 (64) 0.7895
Probucol 1 (3) 1 (3) .0.9999
Fibrates 1 (3) 1 (3) .0.9999
ACE inhibitors 24 (83) 29 (88) 0.7221
Ca Antagonists 5 (17) 6 (18) .0.9999
b-Blockers 24 (83) 29 (88) 0.7221
a-Blockers 1 (3) 0 (0) .0.9999
Cilostazol 3 (10) 3 (9) .0.9999
Angiographic and procedural factors
Target vessel (LAD/RCA) 22/7 25/8 .0.9999
Reference diameter (mm) 3.0 6 0.4 3.0 6 0.4 0.8600
Minimal lumen diameter (mm) 1.0 6 0.1 1.0 6 0.1 0.2502
Diameter stenosis (%) 66.1 6 5.8 67.7 6 5.0 0.3420
Lesion length (mm) 10.5 6 1.2 10.1 6 1.3 0.2042
PS stents/ML stents 12/17 11/22 0.2144
Balloon-artery ratio 1.07 6 0.02 1.07 6 0.03 0.6019
Final balloon pressure (atm) 12.5 6 1.9 12.8 6 2.1 0.7085
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Results of the OGTT are shown in Figure 1 and Table 2.
There were no significant differences in PGs at baseline
between the two groups. At six-month follow-up, however,
PGs after the glucose load in the troglitazone group were
significantly smaller than those in the control group. De-
crease in SPG in the troglitazone group was significantly
greater than that in the control group. There were no
significant differences in insulin levels at baseline between
the two groups. At six-month follow-up, however, insulin
levels in the troglitazone group were significantly smaller
than were those in the control group. The decrease in SIRI
in the troglitazone group was significantly greater than that
in the control group.
Additionally, there were no significant differences in
HbA1c levels between the two groups, either at baseline or
at follow-up. There were no statistically significant differ-
ences in total cholesterol level, triglyceride level, HDL
cholesterol level, or LDL cholesterol level at baseline
between the two groups. Triglyceride level in the troglita-
zone group was significantly smaller than that in the control
group at six-month follow-up, and the percent decrease in
triglyceride levels in the troglitazone group was significantly
greater than that in the control group. The LDL cholesterol
levels in the troglitazone group were significantly greater
than levels in the control group at six-month follow-up.
However, there were no significant differences in the per-
cent change in LDL-cholesterol levels between the two
groups. There were no significant differences in total cho-
lesterol levels or HDL cholesterol levels at follow-up be-
tween the two groups.
Results of quantitative coronary angiography are shown
in Figure 2. There were no significant differences in MLD
between the two groups, either at preintervention (1.0 6
0.1 mm vs. 1.0 6 0.1 mm, respectively, p 5 0.2502) or
postintervention (2.9 6 0.3 mm vs. 2.9 6 0.4 mm,
respectively, p 5 0.9438). However, MLD at follow-up in
the troglitazone group was significantly greater than that in
the control group (2.2 6 0.5 mm vs. 1.7 6 0.5 mm,
respectively, p 5 0.0002).
The results of serial IVUS measurements are shown in
Table 3. There were no significant differences in SA
between the two groups either at post-intervention or
six-month follow-up. However, LA at follow-up in the
troglitazone group was significantly greater than that in the
control group. Both the IA and intimal index at follow-up
in the troglitazone group were significantly smaller than
those in the control group.
DISCUSSION
Using serial IVUS assessments, the present study demon-
strated that troglitazone reduced neointimal tissue prolifer-
ation after coronary stent implantation in patients with
NIDDM. These results suggest that troglitazone can be
effective in preventing restenosis after coronary stent im-
plantation in patients with NIDDM.
Intravascular ultrasound permits direct measurements of
cross-sectional areas of the stent, lumen, and neointimal
tissue in vivo. Using the serial IVUS analysis, Hoffmann et
al. (15) found that the stent did not recoil, and that in-stent
restenosis was the result of neointimal tissue proliferation.
Kornowski et al. (5) reported that the main reason for
increased restenosis in patients with DM was exaggerated
intimal hyperplasia in stented lesions. Diabetes mellitus is
associated with hormonal and vascular abnormalities that
promote vascular smooth muscle cell (VSMC) proliferation
after vascular injury, including injury from catheter-based
interventions (16). Increased VSMC proliferation may re-
sult from mitogens, such as platelet-derived growth factor
(PDGF) and insulin-like growth factor, which stimulate cell
growth (17–19). Insulin resistance and hyperinsulinemia
have been implicated as possible common risk factors for
NIDDM and atherosclerosis (20). Insulin administration
has been suggested to promote VSMC growth (21), and
although it is a weak mitogen alone, in physiologic concen-
trations it promotes the effects of PDGF and other growth
factors of VSMC (22,23). Therefore, treatment strategies
designed to limit cellular proliferation may be efficacious in
reducing in-stent restenosis after coronary stent implanta-
tion in patients with NIDDM who have insulin resistance
and hyperinsulinemia.
Troglitazone is a newly developed anti-diabetic agent
from the thiazolidinedione class, which has been shown to
Figure 1. Plasma glucose levels and insulin levels during the OGTT. No
significant differences were observed in fasting plasma glucose levels and
plasma glucose levels at 1 and 2 h after the glucose load between
troglitazone group and control group at baseline (top, left). However,
plasma glucose levels at 1 and 2 h after the glucose load in troglitazone
group were significantly smaller than those in control group at follow-up
(top, right). No significant differences existed in fasting insulin levels and
insulin levels at 1 and 2 h after the glucose load between two groups at
baseline (bottom, left). However, fasting insulin levels and insulin levels at
1 and 2 h after the glucose load in troglitazone group were significantly
smaller than were those in control group at follow-up (bottom, right).
Closed circle 5 troglitazone group; open circle 5 control group. *p ,
0.05 vs. control group.
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increase insulin sensitivity. The administration of troglita-
zone to patients with NIDDM improves both fasting and
postprandial hyperglycemia and hyperinsulinemia (24–26).
Besides its beneficial effects on the insulin-resistance state,
troglitazone inhibits VSMC growth. Several experimental
studies have reported that troglitazone inhibits growth-
factor-induced proliferation and migration of cultured
VSMC in vitro (6–9,27,28) and reduces intimal hyperplasia
after balloon-induced vascular injury in vivo (6,8). In vitro
studies have revealed that the anti-proliferative effect of
troglitazone stems from its direct action on DNA synthesis
rather than on any accompanying metabolic changes (6–
9,27,28).
The present study demonstrated that administration of
troglitazone benefits patients with NIDDM who have
undergone coronary stent implantation, not only in reduc-
ing PG and insulin levels but also in reducing in-stent
neointimal tissue proliferation. We did not address the
question of what mechanism acts mainly to reduce neoin-
timal tissue proliferation in the clinical setting. Further
studies are necessary to determine which is the main
mechanism of action in reducing neointimal tissue prolifer-
ation after coronary stent implantation in patients with
NIDDM: 1) direct action on DNA synthesis or 2) improve-
ment of the insulin-resistant state (improvement of hyper-
glycemia and/or hyperinsulinemia).
It has been reported that neointimal tissue proliferation
after coronary stent implantation is also accelerated in
patients with impaired glucose tolerance (IGT) (29) and
that hyperinsulinemia in patients with IGT is associated
with increased in-stent neointimal tissue proliferation (30).
Because insulin resistance and hyperinsulinemia are often
present in patients with IGT, the question emerges whether
troglitazone benefits patients with IGT in reducing neoin-
timal tissue proliferation after coronary stent implantation.
Figure 2. Cumulative distribution curves of minimal lumen diameter
(MLD) at preintervention, at postintervention, and at follow-up. Closed
circle, closed square, and closed triangle demonstrate MLD in troglita-
zone group at preintervention, at postintervention, and at follow-up,
respectively. Open circle, open square, and open triangle demonstrate
MLD in control group at preintervention, at postintervention, and at
follow-up, respectively.
Table 2. Results of 75-G Oral Glucose Tolerance Test, Glycosylated Hemoglobin Levels and
Lipid Levels
Troglitazone Group
(n 5 29 stents)
Control Group
(n 5 33 stents) p Value
Fasting plasma glucose baseline (mmol/liter) 5.91 6 0.97 5.93 6 0.80 0.6721
Fasting plasma glucose follow-up (mmol/liter) 5.49 6 0.70 5.74 6 0.90 0.2836
Changes in fasting plasma glucose (%) 25.9 6 11.5 23.3 6 8.1 0.2473
S Plasma glucose baseline (mmol/liter) 32.89 6 9.87 31.35 6 3.07 0.2998
SPlasma glucose follow-up (mmol/liter) 25.82 6 4.75 29.92 6 3.71 ,0.0001
Change in S plasma glucose (%) 221.4 6 8.8 24.5 6 7.4 ,0.0001
Fasting insulin levels baseline (mU/liter) 7.3 6 3.2 7.7 6 2.3 0.2868
Fasting insulin levels follow-up (mU/liter) 5.5 6 2.2 8.3 6 3.0 0.0003
Change in S insulin levels (%) 217.4 6 28.2 7.9 6 31.1 0.0001
S Insulin levels baseline (mU/liter) 209.2 6 91.6 219.6 6 106.2 0.8934
S Insulin levels follow-up (mU/liter) 138.4 6 67.2 220.5 6 127.0 0.0021
Change in S insulin levels (%) 231.4 6 17.9 21.9 6 15.1 ,0.0001
HbA1c baseline (%) 5.9 6 1.0 5.8 6 0.9 0.9045
HbA1c follow-up (%) 5.6 6 0.7 5.7 6 1.0 0.3817
Change in HbA1c (%) 23.6 6 7.8 21.4 6 7.7 0.1312
Total cholesterol baseline (mmol/liter) 5.32 6 0.58 5.21 6 0.63 0.2868
Total cholesterol follow-up (mmol/liter) 5.20 6 0.69 5.21 6 0.50 0.8656
Change in total cholesterol (%) 21.4 6 13.2 1.1 6 11.1 0.4806
Triglyceride baseline (mmol/liter) 1.85 6 0.62 1.99 6 0.91 0.8214
Triglyceride follow-up (mmol/liter) 1.40 6 0.53 2.02 6 0.74 0.0003
Change in triglyceride (%) 220.1 6 26.8 7.8 6 30.4 0.0004
HDL cholesterol baseline (mmol/liter) 1.03 6 0.20 1.02 6 0.24 0.6115
HDL cholesterol follow-up (mmol/liter) 1.14 6 0.23 1.12 6 0.28 0.5919
Change in HDL cholesterol (%) 12.1 6 16.5 12.4 6 25.3 0.6315
LDL cholesterol baseline (mmol/liter) 3.44 6 0.49 3.28 6 0.58 0.1825
LDL cholesterol follow-up (mmol/liter) 3.42 6 0.62 3.17 6 0.42 0.0158
Change in LDL cholesterol (%) 0.6 6 17.8 21.9 6 13.7 0.4850
HbA1c 5 glycosylated hemoglobin A1c; HDL 5 high density lipoprotein; LDL 5 low density lipoprotein.
1533JACC Vol. 36, No. 5, 2000 Takagi et al.
November 1, 2000:1529–35 Troglitazone and Neointimal Tissue Proliferation
Nolan et al. (31) have reported that troglitazone decreases
insulin resistance and improves glucose tolerance in patients
with IGT and/or obesity. Further studies are warranted to
determine whether troglitazone reduces neointimal tissue
proliferation after coronary stent implantation in patients
with IGT. Because of the possibility of drug-induced
hepatocellular injury (32), however, treatment with trogli-
tazone may be limited.
Study limitations. The present study has some intrinsic
limitations. The first is that it is a single-center, non-
placebo-controlled study with a small number of study
patients. A large-scale, multicenter, placebo-controlled
study is warranted to determine whether troglitazone re-
duces angiographic restenosis and/or target lesion revascu-
larization after coronary stent implantation in patients with
NIDDM. The second limitation is our exclusion of patients
with previously treated DM and patients with fasting
glucose levels .7.77 mmol/liter. In these patients, insulin
response to a glucose load may be different because of their
insulin secretory defect. It has been reported that troglita-
zone is effective both when given alone (24–26) and when
given in combination with either sulfonylurea (33), met-
formin (34), or insulin (35). However, further study is
necessary to determine whether troglitazone alone or com-
bined with other oral hypoglycemic agents or insulin can
reduce neointimal tissue proliferation after coronary stent
implantation in NIDDM patients with insufficiency of
insulin secretion.
The third limitation is that analyses of IVUS images at
the central articulation of Palmaz-Schatz stents were ex-
cluded. Several angiographic studies and IVUS studies have
pointed out that the central articulation is the most frequent
site for restenosis in Palmaz-Schatz stents (36,37). How-
ever, recent study using serial IVUS showed that the
tendency for increased neointimal tissue accumulation at the
central articulation was modest in comparison to the oth-
erwise uniform neointimal tissue accumulation over the
length of the stent (15).
Finally, we used the intimal index to estimate neointimal
tissue accumulation over the length of the stent. This
intimal index can underestimate the focal in-stent restenosis
in which the neointimal accumulation is localized. How-
ever, aggressive neointimal growth in the diffuse in-stent
restenosis, which was indicated by a greater intimal index in
this study, has been associated with a higher frequency of
recurrent restenosis after angioplasty than that with focal
in-stent restenosis.
Other glitazones. Recently, two other glitazones were
clinically used. It has been reported that both rosiglitazone
(38) and pioglitazone (39) improve glycemic control in
patients with NIDDM. To our knowledge, however, there
are no reports demonstrating that rosiglitazone reduces
VSMC proliferation. It has been reported that pioglitazone
inhibits growth-factor-induced proliferation of cultured
VSMC in vitro (40) and reduces intimal hyperplasia after
balloon-induced vascular injury in vivo (41). Further studies
are necessary to determine whether other glitazones can
reduce neointimal tissue proliferation after coronary stent
implantation in patients with NIDDM.
Conclusions. Serial IVUS assessment has shown that ad-
ministration of troglitazone reduces neointimal tissue pro-
liferation after coronary stent implantation in patients with
NIDDM.
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